B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Review of Reported Cases
Omar Nadeem1*, Jorge J. Castillo2, Diana O.Treaba1, James N. Butera1
Affiliation
- 1Pharmacology Department; College of Medicine and Health Sciences-UAE University, UAE
- 2Senior Pharmacist, Tawam Hospital, Abu Dhabi Health Services-UAE
Corresponding Author
Omar Nadeem, Brown University, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA, Tel: 401444.5435 ; Fax: 401.444.5256 ; E-mail: onadeem@lifespan.org
Citation
Nadeem, O., et al. B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: A Review of Reported Cases. (2014) J Cancer Oncol 1(1): 1-4.
.
Copy rights
© 2014 Nadeem, O. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Grey Zone Lymphoma (GZL), with features intermediate between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL), is a new entity with limited reported data. A MEDLINE search through July 2013 identified 39 cases of GZL and two additional cases were added from our institution. Comparison of complete remission (CR) rates between ABVD and CHOP-based regimens was performed using Fisher’s exact test. The median age of presentation was 33.5 years with a male predominance (59%), mediastinal involvement (89%), and early stage disease (75%). Patients treated with CHOP-based regimens achieved higher CR rates compared to initial ABVD-based regimens (80% vs. 0%;p=0.01). The 2-yr OS was 87% with a median OS that was not reached. Our reviewindicates this lymphoma subtype to have a high incidence of early stage presentation, mediastinal involvement, B symptoms and overall better outcomes with CHOP-based regimens. Additional studies are warranted to further study this disease.
